Results 51 to 60 of about 156,206 (225)
Adversarial Domain Adaptation for Duplicate Question Detection
, 2018 We address the problem of detecting duplicate questions in forums, which is
an important step towards automating the process of answering new questions.Lei, Tao, Moschitti, Alessandro, Nakov, Preslav, Romeo, Salvatore, Shah, Darsh J +4 morecore +1 more sourcePARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi +13 morewiley +1 more sourceLDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber +13 morewiley +1 more sourceImpact Factor: outdated artefact or stepping-stone to journal
certification?
, 2011 A review of Garfield's journal impact factor and its specific implementation
as the Thomson Reuters Impact Factor reveals several weaknesses in this
commonly-used indicator of journal standing.A Andrade, A Bonillo Perales, A Coleman, A Fassoulaki, A Lomnicki, A Schubert, A Tal, AI Pudovkin, Anonymous, AP Kurmis, AP Kurmis, AR Weale, AW Jones, AW Jones, B Cashore, B Statzner, B Stiftel, B Timuralp, BD Cameron, BM Althouse, C Chen, C Johnson, C McGarty, C Minelli, C Neuhaus, C Scully, CM Ketcham, CP Robert, CR Bain, CW Holsapple, D Ho, D Leutner, D Poomkottayil, D Schoonbaert, D Ugolini, DB Resnik, DB Resnik, DC Greenwood, DE Drew, DN Laband, DR Smith, DW Straub, E Archambault, E Garfield, E Garfield, E Garfield, E Garfield, E Postma, E Wager, EJ Favaloro, EM Sonderstrup-Andersen, EV Bernstam, F Godlee, F Habibzadeh, F Preti, F-T Krell, FJ Bath, FN Dost, G Abramo, G Jacobs, G Knothe, G Lehmkuhl, G Maier, G Racki, G Walter, G Williams, G Winkmann, G Winkmann, G Yu, G Yu, GE Hunt, H Brown, H Goldstein, H Moed, H Sompel Van de, H Xiao, HB Hansen, HF Moed, I Chalmers, I Hames, J Awrey, J Bollen, J Cheek, J Davies, J Horner, J Kapeller, J Mehrad, J Mehrad, J Moller, J Reedijk, J Roberts, J Schopfel, J Woelfel, JA Dempsey, JB Cohen, Jerome K. Vanclay, JJ Ramsden, JK Vanclay, JL Wulff, JM Campanario, JM Campanario, JM Campanario, JP Skovsgaard, JS Kotiaho, JYA Foo, JYA Foo, K Metze, K Simons, K Soreide, KG Altmann, L Bornmann, L Eaton, L Gollogly, L Leydesdorff, L McKeever, L Rieseberg, L Rieseberg, LL Gluud, LL Lange, M Callaham, M Callaham, M Chew, M Driel Van, M Errami, M Errami, M Frank, M Jahangiriana, M Patterson, M Porter, M Rossner, M Rossner, M Taylor, M-J Johnstone, MA Hernan, MA Ruiz, MC Calver, ME Falagas, ME McVeigh, MF Fox, MJ Cobo, MJ Tobin, MV Simkin, N Haslam, N Rezaei-Ghaleh, N Sombatsompop, N Sombatsompop, P Abraham, P Campbell, P Dong, P Jacso, P Jörgensen, P Owlia, PA Lawrence, PA Todd, PA Todd, PC Gøtzsche, PLoS Medicine Editors, PO Seglen, PO Seglen, PO Seglen, R Adler, R Coleman, R Meneghini, R Rousseau, R Rousseau, R Saunders, R Zetterstrom, RA Brumback, RA Brumback, RJ Epstein, RJ Stein, RP Vlosky, RW Glynn, S Butakov, S Chapman, S Lock, S Meyer zu Eissen, S Saha, S Wang, S Woolgar, SE Gwilym, SJ Bensman, SJ Bensman, SJ Bensman, SL Lau, T Braun, TC Ha, TH Berquist, TL Ogden, TN Leeuwen Van, TP Kurmis, TV Perneger, V Barbour, V Kumar, V Larivière, VA Cartwright, W Glänzel, W Glänzel, W Yue, WH Starbuck, WR Schumm, WT Obremskey +201 morecore +1 more sourceTherapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida +10 morewiley +1 more sourceInfrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn +11 morewiley +1 more sourcePhenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer
Molecular Oncology, EarlyView.Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer +9 morewiley +1 more sourceDammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh +8 morewiley +1 more sourceCorrelation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
Molecular Oncology, EarlyView.PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova +10 morewiley +1 more source